Overview

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Status:
RECRUITING
Trial end date:
2035-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Phase:
PHASE2
Details
Lead Sponsor:
Nationwide Children's Hospital
Collaborator:
Accendatech USA Inc.
Treatments:
ACT001